- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01476046
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
9 czerwca 2017 zaktualizowane przez: GlaxoSmithKline
A Two-part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single and Repeat Doses of Intravenously Infused GSK1995057 in Healthy Subjects.
The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing.
The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the body and excreted, and what some of the effects of the study drug are.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Szczegółowy opis
This study will be the first investigation of GSK1995057 in humans and is primarily designed to investigate safety and tolerability of single and repeat intravenously infused doses.
The study will enrol healthy male subjects and healthy female subjects of non-child bearing potential and will also investigate immunogenicity, GSK1995057 distribution (pharmacokinetics), and potential impact on indicators of host immunity and normal immunological function.
Safety, tolerability, immunogenicity, pharmacokinetic and pharmacodynamic data from this trial may facilitate further clinical investigations in healthy subjects dosed with GSK1995057 via the inhaled route, and ultimately clinical trials in patients with acute lung injury.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
56
Faza
- Faza 1
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
Middlesex
-
Harrow, Middlesex, Zjednoczone Królestwo
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 55 lat (Dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician.
- Male or female between 18 and 55 years of age inclusive
- A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea and elevated FSH as per the local laboratory guidelines.
- Normal creatinine clearance values at screening
- Male subjects must agree to use one of the study specific contraception methods
- Body weight ≥ 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive).
- Normal lung function at screening.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Available to complete all study assessments.
- Able to read, comprehend and write English at a sufficient level to complete study elated materials.
Exclusion Criteria:
- A history of Hepatitis B, Hepatitis C or HIV infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities. (With the exception of known Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- Evidence of previous or active mycobacterium tuberculosis complex infection
- Recent history of and/or a positive test for Toxoplasma consistent with active oxoplasmosis infection.
- A positive test for influenza A/B taken within 7 days before dosing.
- Current evidence or history of an influenza-like illness.
- Corrected QT interval (QTcF) >450msec from ECG readings.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol and the following can be used as a guide: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
- The subject is unwilling to abstain from alcohol consumption from 24 hr prior to dosing until discharge from the clinic, and for 24 hr prior to all other out-patient clinic visits.
- Subjects with a smoking history of >10 cigarettes per day in the last 3 months.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) or exposure to more than four new chemical or biological entities within 12 months prior to the first dosing day.
- Subjects having received any type of vaccination within 3 weeks of the anticipated dosing start or are expected to be vaccinated within 3 weeks after the last dose.
- Current evidence of ongoing or acute infection, history of repeated or chronic significant infections or history of serious infection within three months of dosing.
- Subjects who have asthma or a history of asthma, COPD, other respiratory conditions or recurrent infections (a subject who suffered from childhood asthma but not as an adult may be included provided they fulfil other entry criteria).
- Subjects who have a known history of migraine headaches or are frequently suffering from other types of headaches which require medication (frequent defined as more than one headache in a fortnight).
- Use of prescription or non-prescription drugs (except simple analgesics), including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsors Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including severe allergic reaction, angio-edema or anaphylaxis that, in the opinion of the investigator or sponsors Medical Monitor, contraindicates their participation.
- History of malignancy, except for adequately treated non-invasive cancer of the skin (basal or squamous cell) or cervical carcinoma in situ (>2 yrs prior to dosing).
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 3 month or 90 day period.
- Subject is unable to refrain from travelling to countries with a high prevalence of TB or other areas of prevalent infectious disease as judged by the investigator or the sponsors medical monitor from the start of screening until the final follow-up visit.
- Subject is mentally or legally incapacitated.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Randomizowane
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Placebo
Pojedyncza dawka dożylna
|
Single intravenous dose
|
Eksperymentalny: GSK1995057
Single intravenous dose
|
Single intravenous dose
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Occurance of adverse events.
Ramy czasowe: From start of screening until 84 days after completion of single dose (Part A subjects) or first dose (Part B subjects).
|
Number and type of adverse events recorded during study.
|
From start of screening until 84 days after completion of single dose (Part A subjects) or first dose (Part B subjects).
|
Change from baseline in blood pressure.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
Systolic and diastolic blood pressure values before and after dosing completion.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in heart rate.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
Heart rate before and after dosing completion.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in respiration rate.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
Respiration rate before and after dosing completion.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in body temperature.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
Body temperature before and after dosing completion.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in heart function.
Ramy czasowe: For 24hrs during screening, then for 1 hour before dosing to 24 hours after dosing starts (in Part A subjects only, except for cohort 7).
|
Holter recording.
|
For 24hrs during screening, then for 1 hour before dosing to 24 hours after dosing starts (in Part A subjects only, except for cohort 7).
|
Change from baseline in heart function
Ramy czasowe: From 1 hour before dosing to 12 hours after dosing starts for each dose.
|
Lead II cardiac telemetry.
|
From 1 hour before dosing to 12 hours after dosing starts for each dose.
|
Change from baseline in heart function.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
12-lead ECG recording.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in lung function.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
FEV1 and FVC measurements.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Change from baseline in laboratory safety data.
Ramy czasowe: From start of screening until 28 days after completion of single or repeat dosing.
|
Clinical chemistry, haematology and routine urinalysis.
|
From start of screening until 28 days after completion of single or repeat dosing.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Plasma pharmacokinetics of GSK1995057
Ramy czasowe: From the first day of dosing until 48 hours after the completion of dosing.
|
Levels of GSK1995057 in blood samples.
|
From the first day of dosing until 48 hours after the completion of dosing.
|
Urine pharmacokinetics of GSK1995057
Ramy czasowe: From 1 hour before the only dose until 48 hours after the dose.
|
Levels of GSK1995057 in urine samples from cohort 6 subjects only.
|
From 1 hour before the only dose until 48 hours after the dose.
|
Bronchoalveolar lavage fluid (BALF) (saline flushed into and then collected from a lung) pharmacokinetics.
Ramy czasowe: At 2 hrs after the completion of the only dose.
|
Levels of GSK1995057 in BALF from cohort 7 subjects only.
|
At 2 hrs after the completion of the only dose.
|
Effect of GSK1995057 on host immunity and immunological function
Ramy czasowe: From the day before dosing starts to 28 days after dosing completion.
|
Levels of pharmacodynamic and immune function biomarkers in blood samples.
|
From the day before dosing starts to 28 days after dosing completion.
|
Effects of GSK1995057 on host immunity and immunological function
Ramy czasowe: At 2 hrs after the completion of the only dose.
|
Levels of pharmacodynamic and immune function biomarkers in BALF from cohort 7 subjects only.
|
At 2 hrs after the completion of the only dose.
|
Immunogenic effect of GSK1995057
Ramy czasowe: From the start of screening (cohorts 1-4 only) or from the day before the start of dosing until 84 days after the completion of single or repeat dosing.
|
Levels of anti-GSK1995057 antibodies in blood samples
|
From the start of screening (cohorts 1-4 only) or from the day before the start of dosing until 84 days after the completion of single or repeat dosing.
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
8 marca 2011
Zakończenie podstawowe (Rzeczywisty)
17 czerwca 2012
Ukończenie studiów (Rzeczywisty)
17 czerwca 2012
Daty rejestracji na studia
Pierwszy przesłany
15 marca 2011
Pierwszy przesłany, który spełnia kryteria kontroli jakości
17 listopada 2011
Pierwszy wysłany (Oszacować)
22 listopada 2011
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
12 czerwca 2017
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
9 czerwca 2017
Ostatnia weryfikacja
1 czerwca 2017
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 110951
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
TAK
Opis planu IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Badanie danych/dokumentów
-
Specyfikacja zestawu danych
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Protokół badania
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz świadomej zgody
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Indywidualny zestaw danych uczestnika
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz zgłoszenia przypadku z adnotacjami
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan analizy statystycznej
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Raport z badania klinicznego
Identyfikator informacji: 110951Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na GSK1995057 single dose
-
University of South CarolinaMedical University of South Carolina; National Institute on Deafness and Other...Zakończony
-
University of MinnesotaRekrutacyjnyPrzeszczep narządów stałychStany Zjednoczone
-
Goztepe Training and Research HospitalZakończonyChoroba zwyrodnieniowa stawówIndyk
-
Caldera Medical, Inc.Rekrutacyjny
-
DD-Hippero s.r.o.PharmTest s.r.o.; Prague Clinical Services s.r.o.ZakończonyBól pleców | Zaburzenia kręgosłupa | Choroba Kręgosłupa LędźwiowegoCzechy
-
GlaxoSmithKlineZakończonyZaburzenia układu oddechowegoZjednoczone Królestwo
-
Sanofi Pasteur, a Sanofi CompanyZakończony
-
Melinda SeeringJeszcze nie rekrutacjaZnieczulenie | Ból pooperacyjny | Choroba zwyrodnieniowa stawu barkowego | Blok nerwowyStany Zjednoczone
-
Albert Einstein Healthcare NetworkRekrutacyjnyPowikłania cięcia cesarskiego | Infekcja ranyStany Zjednoczone
-
Columbia UniversitySociety of Family PlanningZakończonyAborcja w pierwszym trymestrzeStany Zjednoczone